| Name | Title | Contact Details |
|---|---|---|
Janet G. |
Head of Security | Profile |
Satnam Alag |
Senior Vice President of Software Engineering | Profile |
Angela Lai |
Chief Technology Officer | Profile |
Established in 1960, the Healthcare of Ontario Pension Plan (HOOPP) is a multi-employer defined benefit pension plan for Ontario`s hospital and community-based healthcare sector. We serve more than 435,000 members who provide valued healthcare services at more than 630 employers across the province. At HOOPP, we exist to provide a stable and reliable pension for our members that starts in retirement and is paid for life. As one of Canada`s largest and most respected pension plans, HOOPP`s net assets reached $103.7 billion at the end of 2022 and our funded status remained strong at 117%. HOOPP`s core values - professional, accountable, collaborative, compassionate and trustworthy - guide our every interaction with our members, employers and employees. We`ve become one of Canada`s leading pension plans by consistently challenging ourselves and embracing innovation. From our unique investment management approach to our innovative technology and thought-provoking research, we constantly seek to push the boundaries, and we do this by hiring passionate, forward-thinking people. Our high-performance culture is founded on collaboration, respect and belonging. HOOPP is an equal opportunity employer and we`re proud of our diversity. We select applicants for employment solely on the basis of their qualifications. Should you require accommodation because of a disability during the recruitment and selection process, please contact our Human Resources team. We will be happy to consult with you so that arrangements can be made for reasonable accommodation.
Florida Hospital Orlando is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioHitech America is the industry leader in the development of a simple, cost-effective food waste disposal technology designed to solve today’s landfill diversion and sustainability objectives. The Eco-Safe Digester handles food waste at the point of generation, no residual food waste to store or transport. The Eco-Safe Digester can convert up to 2,400 pounds of food waster per day into a nutrient-neutral grey water that can safely be disposed of via municipal sewer systems. The Eco-Safe Digester saves money by avoiding disposal costs and significantly reduces greenhouse gas emissions by providing a sustainable means of transportation for the waste by-product with doesn’t require on-road transportation. The Eco-Safe Digester’s cloud-based management solution is designed to measure and collect food waste data. It correlates information to report cost savings and environmental reductions as well as communicate opportunities to prevent waste altogether. This modifiable data can also be used to assess the performance of your staff and predict trends for smarter budgeting and purchasing purposes. In addition to diverting food waste from landfills and converting food waste into a resource, the machine is now poised for significant growth in this emerging data-driven zero waste initiative climate because it identifies waste in order to prevent the creation of it all together. Already implemented in many applications across the globe, the Eco-Safe Digester is ideal for use in any food service, hospitality, healthcare, government, conference center, education center, or stadium that generates a high volume of waste.
Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.